Travere Therapeutics presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 10, 2026. Chief Financial Officer Chris Cline highlighted a cash position of $489 million at the end of the most recent quarter and said the company has no near‑term capital requirements.
Management estimated that FILSPARI, the company’s dual endothelin‑angiotensin blocker approved for IgA nephropathy and focal segmental glomerulosclerosis (FSGS), could generate more than $3 billion in peak sales across both indications. Gross‑to‑net deductions are expected to fall in the mid‑20 percent range. A recent methods‑of‑use patent for IgA nephropathy extends protection to 2037, with a similar FSGS patent pending that would also reach 2037 if granted.
The FSGS launch exceeded expectations, delivering two and a half months of revenue in the first quarter after approval. Seventy percent of prescribers had prior experience with FILSPARI in IgA nephropathy, while the remaining 30 percent were new to the product, most initially writing a single prescription.
Travere’s pipeline includes pegtibatinase for classical homocystinuria (HCU), with Phase III HARMONY results slated for the second half of 2027. Manufacturing optimization for the HCU program was completed late last year, enabling commercial‑scale batch production and the restart of enrollment activities.
Addressable markets were outlined: roughly 70,000 IgA nephropathy patients, over 30,000 primary FSGS patients (up to 40,000 when secondary cases are included), 7,000‑10,000 HCU patients, and about 90,000 primary membranous nephropathy patients. Payer mixes are projected to be predominantly commercial, with a higher share of CMS coverage for FSGS and HCU.
Other assets discussed were civo‑brutinib, an in‑licensed BTK inhibitor with early proof‑of‑concept data in primary membranous nephropathy, and Vanrafia (atrasentan), a single endothelin inhibitor marketed by Novartis that serves as a competitive reference.
